(Q52096214)

English

Treatment of recurrent ovarian cancer: a retrospective analysis of women treated with single-agent carboplatin originally treated with carboplatin and paclitaxel. The Memorial Sloan-Kettering Cancer Center experience.

scientific article published in December 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

22 April 2018

http://europepmc.org/abstract/MED/14675681

Treatment of recurrent ovarian cancer: a retrospective analysis of women treated with single-agent carboplatin originally treated with carboplatin and paclitaxel. The Memorial Sloan-Kettering Cancer Center experience. (English)

1 reference

Europe PubMed Central

PubMed publication ID

22 April 2018

http://europepmc.org/abstract/MED/14675681

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Carol Aghajanian

6

object named as

Carol Aghajanian

1 reference

Europe PubMed Central

PubMed publication ID

22 April 2018

http://europepmc.org/abstract/MED/14675681

author name string

Don S Dizon

1

1 reference

Europe PubMed Central

PubMed publication ID

22 April 2018

http://europepmc.org/abstract/MED/14675681

Jakob Dupont

2

1 reference

Europe PubMed Central

PubMed publication ID

22 April 2018

http://europepmc.org/abstract/MED/14675681

Sibyl Anderson

3

1 reference

Europe PubMed Central

PubMed publication ID

22 April 2018

http://europepmc.org/abstract/MED/14675681

Paul Sabbatini

4

1 reference

Europe PubMed Central

PubMed publication ID

22 April 2018

http://europepmc.org/abstract/MED/14675681

Amanda Hummer

5

1 reference

Europe PubMed Central

PubMed publication ID

22 April 2018

http://europepmc.org/abstract/MED/14675681

David Spriggs

7

1 reference

Europe PubMed Central

PubMed publication ID

22 April 2018

http://europepmc.org/abstract/MED/14675681

language of work or name

0 references

publication date

1 December 2003

1 reference

Europe PubMed Central

PubMed publication ID

22 April 2018

http://europepmc.org/abstract/MED/14675681

Gynecologic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

22 April 2018

http://europepmc.org/abstract/MED/14675681

91

1 reference

Europe PubMed Central

PubMed publication ID

22 April 2018

http://europepmc.org/abstract/MED/14675681

3

1 reference

Europe PubMed Central

PubMed publication ID

22 April 2018

http://europepmc.org/abstract/MED/14675681

584-590

1 reference

Europe PubMed Central

PubMed publication ID

22 April 2018

http://europepmc.org/abstract/MED/14675681

Cancer statistics, 2003.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.08.017

7 January 2021

Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.08.017

7 January 2021

Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.08.017

7 January 2021

Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.08.017

7 January 2021

Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.08.017

7 January 2021

Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.08.017

7 January 2021

Second-line therapy for potentially platinum-sensitive recurrent ovarian cancer: what is optimal treatment?

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.08.017

7 January 2021

Salvage chemotherapy for epithelial ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.08.017

7 January 2021

Paclitaxel and cisplatin combination chemotherapy in recurrent epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.08.017

7 January 2021

Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.08.017

7 January 2021

Prognostic factors in advanced epithelial ovarian cancer. (Gruppo Interregionale Cooperativo di Oncologia Ginecologica (GICOG))

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.08.017

7 January 2021

Prognostic factors in advanced ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.08.017

7 January 2021

Outcome of epithelial ovarian cancer in women under 40 years of age treated with platinum-based chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.08.017

7 January 2021

Identifiers

10.1016/J.YGYNO.2003.08.017

1 reference

Europe PubMed Central

PubMed publication ID

22 April 2018

http://europepmc.org/abstract/MED/14675681

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

22 April 2018

http://europepmc.org/abstract/MED/14675681

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q52096214&oldid=2046272142"